Contact Information
37 Westminster Buildings, Theatre Square,
Nottingham, NG1 6LG
DIGITEC hires BNY Mellon/LSEG alum Christopher Johnson to head new Singapore office
Just a few days removed from expanding its London operation, Hamburg based FX Swaps and NDF pricing and data provider DIGITEC has announced the opening
Goldman Sachs, Johnson & Johnson fall premarket; Carvana, Microsoft rise By Investing.com
© Reuters Investing.com — U.S. traded largely unchanged Wednesday, consolidating after recent strong gains as investors digest a deluge of important corporate earnings. Here are
Johnson & Johnson Sues Doctors Over Studies Linking Talc-Based Products and Cancer
Company says the studies played a significant role in lawsuits over its Baby Powder and Shower to Shower products. Source link
Stocks Withstand Earnings-Day Declines From Goldman Sachs, Johnson & Johnson
Bank of America was among the other big companies reporting Tuesday. Source link
Johnson & Johnson Posts Higher Quarterly Sales, Raises 2023 Outlook
First-quarter earnings were largely wiped out by a $6.9 billion charge tied to litigation and other costs from its Covid-19 vaccine commitments. Source link
Johnson & Johnson’s Talc Plan Spotlights Chapter 11 Voting Power
Johnson & Johnson’s latest plan to resolve mass cancer lawsuits through bankruptcy could force some cosmetic-talc users and their lawyers into a settlement they don’t
Exxon Mobil, Johnson & Johnson, Alphabet: Stocks That Defined the Week
Markets Stocks Here are seven major companies whose stocks moved on the week’s news Source link
Johnson & Johnson Proposes Paying $9 Billion to Settle Talc Lawsuits
A unit of the health-products company is also refiling for bankruptcy protection to seek approval for the settlement plan. Source link
Exclusive-Johnson & Johnson considers refiling talc-liability bankruptcy after appeals-court defeat By Reuters
© Reuters. FILE PHOTO: The Johnson & Johnson logo is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in
Johnson & Johnson Rips Off the Kenvue Band-Aid
A surprisingly early distribution and a stretched valuation hit J&J’s consumer health arm hard. Source link